South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Thailand Inflation Remains Negative for 10th Straight Month in January 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
